Beneficial dysregulation of the time course of inflammatory mediators in lipopolysaccharide-induced tumor necrosis factor alpha factor-deficient mice

Clinical and Vaccine Immunology

Volumn 17, Issue 5, 2010, Pages 699-704

  Srinivasan, Sreedevi ^a   Leeman, Susan E ^b   Amar, Salomon ^a  

^a BOSTON UNIVERSITY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; EOTAXIN; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; GALACTOSAMINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 9; KERATINOCYTE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN KINASE B; RANTES; S6 KINASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FOLLOW UP; IMMUNOREGULATION; INFLAMMATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SURVIVAL; WILD TYPE;

ANIMALS; GENE EXPRESSION PROFILING; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED C57BL; PROTEIN KINASES; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77951988106     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00510-09     Document Type: Article

References (26)

1. Beutler, B., and A. Cerami. 1989. The biology of cachectin/TNF - a primary mediator of the host response. Annu. Rev. Immunol. 7:625-655.
2. Bradford, M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254.
3. Brunet, A., A. Bonni, M. J. Zigmond, M. Z. Lin, P. Juo, L. S. Hu, M. J. Anderson, K. C. Arden, J. Blenis, and M. E. Greenberg. 1999. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96:857-868.
4. Cardone, M. H., N. Roy, H. R. Stennicke, G. S. Salvesen, T. F. Franke, E. Stanbridge, S. Frisch, and J. C. Reed. 1998. Regulation of cell death protease caspase-9 by phosphorylation. Science 282:1318-1321.
5. Clauss, M., C. Sunderkotter, B. Sveinbjornsson, S. Hippenstiel, A. Willuweit, M. Marino, E. Haas, R. Seljelid, P. Scheurich, N. Suttorp, et al. 2001. A permissive role for tumor necrosis factor in vascular endothelial growth factor-induced vascular permeability. Blood 97:1321-1329.
6. Datta, S. R., H. Dudek, X. Tao, S. Masters, H. Fu, Y. Gotoh, and M. E. Greenberg. 1997. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91:231-241.
7. Domina, A. M., J. A. Vrana, M. A. Gregory, S. R. Hann, and R. W. Craig. 2004. MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or Taxol. Oncogene 23:5301-5315.
8. Erhardt, P., E. J. Schremser, and G. M. Cooper. 1999. B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway. Mol. Cell. Biol. 19:5308-5315.
9. Ettehadi, P., M. W. Greaves, D. Wallach, D. Aderka, and R. D. Camp. 1994. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin. Exp. Immunol. 96:146-151.
10. Fiorentino, D. F., A. Zlotnik, T. R. Mosmann, M. Howard, and A. O'Garra. 1991. IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147:3815-3822.
11. Frodin, M., and S. Gammeltoft. 1999. Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Mol. Cell. Endocrinol. 151:65-77.
12. Haider, S., and M. Knofler. 2009. Human tumour necrosis factor: physiological and pathological roles in placenta and endometrium. Placenta 30: 111-123.
13. Lehmann, V., M. A. Freudenberg, and C. Galanos. 1987. Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine- treated mice. J. Exp. Med. 165:657-663.
14. Lucas, M., X. Zhang, V. Prasanna, and D. M. Mosser. 2005. ERK activation following macrophage Fc(gamma)R ligation leads to chromatin modifications at the IL-10 locus. J. Immunol. 175:469-477. (Pubitemid 40884351)
15. Neale, M. L., B. D. Williams, and N. Matthews. 1989. Tumour necrosis factor activity in joint fluids from rheumatoid arthritis patients. Br. J. Rheumatol. 28:104-108.
16. Osuchowski, M. F., K. Welch, J. Siddiqui, and D. G. Remick. 2006. Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J. Immunol. 177:1967-1974.
17. Pengal, R. A., L. P. Ganesan, G. Wei, H. Fang, M. C. Ostrowski, and S. Tridandapani. 2006. Lipopolysaccharide-induced production of interleukin-10 is promoted by the serine/threonine kinase Akt. Mol. Immunol. 43:1557-1564.
18. Remick, D. G., R. G. Kunkel, J. W. Larrick, and S. L. Kunkel. 1987. Acute in vivo effects of human recombinant tumor necrosis factor. Lab. Invest. 56:583-590.
19. Rothe, J., W. Lesslauer, H. Lotscher, Y. Lang, P. Koebel, F. Kontgen, A. Althage, R. Zinkernagel, M. Steinmetz, and H. Bluethmann. 1993. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364:798-802.
20. Scheid, M. P., and V. Duronio. 1998. Dissociation of cytokine-induced phosphorylation of Bad and activation of PKB/Akt: involvement of MEK upstream of Bad phosphorylation. Proc. Natl. Acad. Sci. U. S. A. 95:7439-7444.
21. Shiomi, N., F. Myokai, K. Naruishi, K. Oyaizu, K. Senoo, T. Yamaguchi, S. Amar, and S. Takashiba. 2006. Cloning and characterization of lipopolysaccharide-induced tumor necrosis factor α factor promoter. FEMS Immunol. Med. Microbiol. 47:360-368.
22. Tang, X., M. J. Fenton, and S. Amar. 2003. Identification and functional characterization of a novel binding site on TNF-alpha promoter. Proc. Natl. Acad. Sci. U. S. A. 100:4096-4101.
23. Tang, X., D. L. Marciano, S. E. Leeman, and S. Amar. 2005. LPS induces the interaction of a transcription factor, LPS-induced TNF-alpha factor, and STAT6 (B) with effects on multiple cytokines. Proc. Natl. Acad. Sci. U. S. A. 102:5132-5137.
24. Tang, X., D. Metzger, S. Leeman, and S. Amar. 2006. LPS-induced TNF-alpha factor (LITAF)-deficient mice express reduced LPS-induced cytokine: evidence for LITAF-dependent LPS signaling pathways. Proc. Natl. Acad. Sci. U. S. A. 103:13777-13782.
25. Tracey, K. J., B. Beutler, S. F. Lowry, J. Merryweather, S. Wolpe, I. W. Milsark, R. J. Hariri, T. J. Fahey III, A. Zentella, J. D. Albert, et al. 1986. Shock and tissue injury induced by recombinant human cachectin. Science 234:470-474.
26. Van Deventer, S. J. 1997. Tumour necrosis factor and Crohn's disease. Gut 40:443-448. (Pubitemid 27204920)